Axplora invests $30 million in lyophilization at Le Mans site, boosting ADC production. Facilities enhance control, reliability, and traceability.

Research-backed strategy produces highly homogeneous antibody-drug conjugates (gsADCs) with consistent DAR and tumor suppression lasting over 50 days after a single dose A new white paper from ...

WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a leading global CRDMO (Contract Research, Development, and Manufacturing Organization) specializing in antibody-drug conjugates (ADCs) and ...

Antibody drug conjugates have fast become a big piece of AstraZeneca’s revenue growth. The drugmaker is taking steps to ensure it has the production capacity to meet market demand for these cancer ...

The "ADC Contract Manufacturing Market: Industry Trends and Global Forecasts, till 2035 - Distribution by Stage of Development, Process Component, Target Indication, Antibody Generation, Antibody ...

Less than a month after unveiling a peptide expansion at its production site in Mourenx, CDMO Axplora has hit the gas on a capacity-building project at another French plant. Axplora is bulking up at ...

Triples manufacturing capacity to meet increased global demand for antibody-drug conjugates (ADCs) Reinforces position as first commercially approved contract development and manufacturing ...

First scalable single-use mixer specifically designed for ADC manufacturing Increases efficiency by 70% compared to stainless steel or glass manufacturing methods Utilizes Ultimus ® Film for superior ...

-- Chime Biologics and Waterstone Pharmaceuticals announce a strategic partnership to provide integrated services for the global Antibody-Drug Conjugate (ADC) industry. -- Chime Biologics will ...

With the precision of monoclonal antibodies and the potency of small-molecular payloads, antibody-drug conjugates (ADC) are promising cancer therapeutics. As of this year, there are 19 ADC drugs ...

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany (Merck KGaA), invested $76 million to expand its antibody drug conjugate (ADC) manufacturing capabilities ...